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 Skeletal muscle atrophy is defined as a 5% or greater loss of muscle mass that occurs with 
muscle disuse, muscle and neural injuries, disease (e.g., cancer, diabetes), and also happens naturally 
with aging.  Atrophy results from an imbalance of protein degradation and protein synthesis which 
produces a net loss of protein. The protein loss occurs mostly through three proteolytic systems: Calpain 
enzymes, cathespin enzymes, and the largest contributor, the ubiquitin proteasome pathway (UPP). The 
ether-a-go-go related gene (ERG1A) is a voltage gated K+ channel that is upregulated in atrophying 
skeletal muscle. Expression of ERG1A in skeletal muscle increases UPP activity and induces atrophy. 
Initial immunohistochemistry suggested that ERG1A might be more abundant in certain muscle fibers. 
Indeed, skeletal muscle fibers vary in their composition of the myosin heavy chain (MyHC) proteins 
which participate in muscle contraction. MyHC composition determines muscle fiber contraction speed, 
producing a slow-twitch fiber type and a number of fast-twitch fiber types. Different muscles are 
composed of varying numbers of fast and slow-twitch fibers which produce their specific contraction 
speed. Because ERG1A appears variably expressed in muscles composed of mixed fiber types and is a K+ 
channel which has the potential to modulate contraction speed by enhancing repolarization, we 
hypothesized that ERG1A would be more abundant in slow-twitch fibers than in fast-twitch fibers in 
skeletal muscle.  To test this hypothesis, we cryo-sectioned Soleus (SOL), Extensor Digitorum Longus 
(EDL), and Gastrocnemius muscles of rats. These muscles were chosen because the SOL and EDL have an 
abundance of slow and fast-twitch fibers, respectively, while the Gastrocnemius contains a more 
heterogeneous composition. The sections were co-immunostained for the ERG1A protein and either the 
fast or slow-twitch MyHC. ERG1A fluorescence was measured in the sarcolemma of each fiber type and 
compared.  The data reveal that the ERG1A protein is more abundant in muscle fibers of the Sol than in 
the EDL; however, these muscles are very homogeneous in terms of fiber type so it was not possible to 
get enough data from both fiber types within a muscle to compare ERG1A composition in each.  
Therefore, we immunostained fibers from the heterogeneous Gastrocnemius muscle.  The data reveal 
that ERG1A is 3.2-fold greater in slow than in fast fibers in this muscle.  This knowledge will allow us to 
concentrate our investigations into the role of ERG1A in the development of atrophy on muscles in 
which ERG1A is most highly abundant.  Indeed, atrophy is a potentially debilitating condition for which 
there is no truly effective pharmacological treatment.  Currently, exercise and diet are the best 
treatments to combat atrophy; however, sick and elderly individuals may not be able to participate in 
this effectively. Thus, further research into the mechanism(s) that regulate muscle atrophy is necessary 





 Skeletal muscle comprises 35-45% of the human body mass and is critical for movement, 
posture, and temperature regulation. Skeletal muscle atrophy is a debilitating condition that occurs with 
many different diseases (e.g., cancer cachexia, HIV/AIDS, and diabetes), injury (e.g. spinal cord damage 
or denervation), disuse, fasting, and glucocorticoid treatment. Skeletal muscle atrophy also occurs with 
normal aging and space flight (Ma, et al., 2017; Frontera and Ochala 2015; Bonaldo and Sandri 2013; 
Baoge et al., 2012; Smith et al., 2008).  Muscle atrophy occurs because there is an imbalance in protein 
degradation and protein synthesis that results in a net loss of muscle protein.  The majority of muscle 
degradation results from the activity of three proteolytic systems: calpains, cathespins, and the ubiquitin 
proteasome pathway (UPP, also known as the ubiquitin proteolysis pathway). It has been shown that 
the UPP is the primary proteolytic system involved in skeletal muscle atrophy and is suggested to be 
responsible for as much as 75% of protein breakdown (Kandarian et al. 2006; Glass 2003; Franch et al. 
2005).  Skeletal muscle atrophy has been linked with increased human morbidity and mortality, 
however, there are no reliable pharmaceutical therapies to combat this problem.  Indeed, the best 
treatment for atrophy is good diet and exercise; however, not all people are able to be active (Bonaldo 
and Sandri 2013; Baoge et al., 2012; Lynch and Ryall 2008; Derbre et al., 2012; Fareed, et al., 2006; 
Guasconi and Puri 2008; Han and Mitch 2011; Smith and Lin 2013).  Therefore, new therapies for 
atrophy would greatly benefit medical practice and this can only happen if research reveals new targets 
for treatment. 
Skeletal Muscle Fiber Types 
Skeletal muscle is composed of muscle fibers which are made up of contractile units called 
sarcomeres (Figure 1).  Each sarcomere is bordered by a Z-disk on each end with a line of proteins in the 
center which make up the M-line.  The myosin heavy chain (MyHC) proteins, which are the main 
components of the thick filaments, are connected to the M-line and extend outward from there toward 
the Z disk.  The thin filaments, which are connected to the Z-disk proteins by anchor proteins (e.g., titin), 
are mainly composed of actin proteins.  Calcium ions bind to troponin proteins located on the thin 
filament proteins and move tropomyosin to expose sites on the actin to which the MyHCs can bind.  The 
MyHC heads bind to the actin forming cross bridges which change conformation, bending like a ratchet 
Figure 1.  Sarcomere: The skeletal muscle contractile unit.WW 
and causing an overlap of the thin and thick filaments.  This interaction can be released and then 
repeated so that the thin and thick filaments interdigitate and become smaller, resulting in muscle 
contraction.  ATP is used to promote the release of the filament interaction and resulting in muscle 
relaxation.   
Skeletal muscle fibers vary in their speed of contraction (fast or slow), resistance to fatigability (high or 
low), and main metabolic pathway for energy production (aerobic or anaerobic).  They are generally 
referred to in terms of speed of contraction and the main fibers described are slow-twitch (Type 1) or 
fast-twitch fibers (Type 2A, 2X, or 2B).  Others have been described, but those are generally muscle 
specific and/or not abundant.  The difference in the speed of contraction is determined by the myosin 
heavy chain (MyHC) proteins which compose the thick filaments of the skeletal muscle (Table 1).  
Table 1.  Myosin heavy chain proteins detected in rodents. 
Genes  Proteins  Expression pattern 
MYH2 MyHC-2A  Fast type 2A fibers 
MYH1 MyHC-2X  Fast type 2X fibers 
MYH4 MyHC-2B  Fast type 2B fibers 
MYH7 MyHC-  Heart and slow muscles 
MYH3 MyHC-emb  Developing Muscle 
 
Slow-twitch fibers generally contain the MyHC- protein which is encoded by the MYH7 gene.  Fibers 
with this protein produce ATP mainly by aerobic metabolism, being more resistant to fatigue.  Fast 
contracting fibers mainly contain one or more of the fast MyHC proteins: MyHC-2A, MyHC-2B, or MyHC-
2X.  Fast fibers vary in speed of contraction from 2A, 2X, to 2B with the 2A being the slower and the 2B 
being the fastest.  They also vary in terms of the main form of metabolism used to produce ATP, with 2A 
relying more on aerobic metabolism and 2X and 2B relying more upon the anaerobic pathway.  
Consequently, 2A is more fatigue resistant than 2X and both 2A and 2X are more fatigue resistant than 
2B (Schiaffino 2018; Schiaffino and Reggiani 2011).  Muscles may contain mainly one type of fiber or be 
composed of numerous types in various combinations. This variability gives muscle a great deal of 
flexibility in a muscle’s ability to generate force and movement.  It appears to be the impulse which 
determines the fiber type developmentally.  Chronic, slow neural impulses produce slow-twitch fibers 
while faster impulses will result in development of fast-twitch fibers.  However, muscle has a great deal 
of plasticity and fiber type can change even in adult muscle.  For example, cross-reinnervation can 
change fiber type:  fast muscles turn slow when reinnervated with a slow nerve and slow muscles turn 
fast when reinnervated by a fast nerve.  With application of electrical stimulation, chronic slow 
frequency stimulation of denervated slow muscles can maintain a slow fiber phenotype.  Chronic slow 
frequency stimulation of denervated muscles expressing mainly fast-twitch fibers can switch them to 
slow fiber type and vice versa.  These data further demonstrate that neural input determines the fiber 
type (Schiaffino and Reggiani 2011; Liu et al., 2015).  Human skeletal muscle contains three main types 
of fibers: Type 1, 2A and 2X.  To date, only trace amounts of 2B are detected.  The four main fiber types 
described above are found in rodents.  In rats, the Gastrocnemius muscle contains a heterogeneous 
composition of fiber type, having both fast and slow-twitch fibers (Chabowski et al., 2006).  The Extensor 
digitorum longus muscle in rats is composed mainly of fast-twitch fibers (Close 1967) while the Soleus 




The ether-a-gogo related gene 1 
(ERG1A) encodes a potassium 
channel that is partially responsible 
for repolarization of the cardiac 
action potential.  The ERG1A protein 
has six membrane-spanning 
domains, a conserved pore domain, 
and an N-terminus with numerous 
potential signaling domains (Figure 
2) [Vandenberg et al., 2012; Jones et 
al., 2004].   Numerous alternative 
splice variants have been reported, 
but it is the ERG1A and ERG1B gene 
products which are detected in 
cardiac tissue (Figure 3; London et 
al., 1997; Lees-Miller et al., 1997).  
Indeed, a heteromultimeric channel 
composed of these two variants is 
reported to contribute to cardiac 
repolarization; and mutations in the 
ERG1A gene are known to cause a 
heart arrhythmia known as Long QT Syndrome 2.  The ERG1A protein is detected in heart, but also it has 
been reported in brain, smooth muscle of numerous mammalian species, and various cancer cells 
[London et al., 1997; Vandenberg, et al., 2012].  The alternative splice variant ERG1B subunit is 
essentially identical to the 1A variant except that is has a truncated N-terminus.  The 1B is considered to 
be a cardiac specific isoform (Andersen et al.1997, Andersen et al. 2000), although there are reports of 
its detection in brain and cancer cells (Lees-Miller et al., 1997, London et al., 1997) Recently, it has been 
shown that in rodents the ERG1A K+ channel variant is upregulated in skeletal muscle atrophying in 
response to either disuse or cancer cachexia (Wang et al., 2006).  Additionally, when ERG1A is 
ectopically expressed in the Gastrocnemius muscles of mice, abundance of the UPP E3 ligase MuRF1 is 
increased, UPP activity is increased, and myofiber size decreases significantly (Wang et al., 2006).  The 
data suggest that ERG1A plays a role in the mechanism(s) producing skeletal muscle atrophy. 
Hypothesis 
ERG1A is a potassium channel known to repolarize the cardiac action potential.  It has been detected in 
atrophying skeletal muscle, however, it is not known if the ERG1A channel contributes to the atrophic 
process or is up-regulated to combat this process.  The up-regulation of the MuRF1 E3 ligase and 
increased UPP activity strongly suggest that it contributes to atrophic mechanisms.  Because it has the 
potential to repolarize membranes and, thereby, decrease action potential duration, we hypothesized 
that ERG1A could slow muscle contraction and thus be more abundant in slow-twitch muscle fibers than 
in fast-twitch muscle fibers.  
To test this hypothesis, we used immunohistochemistry to measure ERG1A fluorescence in the muscle 
fibers of both the Sol and EDL muscles.  We intended to compare ERG1A fluorescence in each fiber type 
within a muscle; however, because each muscle is truly nearly homogeneous in terms of fiber type 
composition, we were unable to compare ERG1A fluorescence per fiber type within muscle.  
Nonetheless, we did discover that ERG1A is more abundant in Soleus muscle, where slow-type fibers are 
more abundant, than in the EDL muscle which is composed of mainly fast-type fibers.  These results 
were confirmed with immunoblots of muscles from old and young rats.  To look at specific fiber type 
composition, we needed to test ERG1A abundance in a muscle that had a more heterogeneous 
composition of fiber types.  Thus, we used immunohistochemistry to co-immunostain Gastrocnemius 
muscle for ERG1A and a fiber type specific myosin heavy chain (MyHC) protein.  We then measured 
ERG1A fluorescence in each fiber type to determine if there was a difference in abundance of the ERG1A 
K+ channel between slow-twitch and fast-twitch muscle fibers. 
 
Methods 
Animals.  All procedures were approved by the SIU SOM Animal Care and Use Committee.  Soleus, 
Extensor digitorum longus, and Gastrocnemius muscles from FDB rats (NIH; Bethesda, MD) at both 3 and 
30 months of age were generously provided by Dr. Don Torry (SIU SOM).   
Cryo-sectioning.  Muscles were embedded in OCT Compound and cross sectioned at 20 um using a Leica 
cryostat microtome. 
Immunohistochemistry (IHC).  Muscle sections were not fixed.  They were incubated with 3% hydrogen 
peroxide (15 minutes) and then rinsed with PBS.  Next they were dipped in 0.3% Sudan black in PBS 
containing 0.5% triton X-100 for 30 seconds and then rinsed with PBS.  The sections were incubated in 
blocking buffer (5% NGS + 2% Tritonx-100 in PBS) for one hour and then incubated with either anti-slow 
or anti-fast MyHC mouse primary antibody at room temperature also for an hour.  One section per 
muscle was not incubated with the primary antibody as control.  The sections were then rinsed with 
PBS.  Non-control sections were incubated in an in-house anti-ERG1A primary antibody (Pond et al., 
1999) overnight.  After incubation, the sections were rinsed and secondary antibodies (goat anti-mouse 
IgG labelled with Alexa-fluor 568 and goat anti-rabbit IgG conjugated with HRP-tyramide Alexa-fluor 
488) were mixed and applied to all sections, including controls, at room temperature for 1 hour.  
Sections were then rinsed with PBS.  The ERG1A signal was developed using a Tyramide kit (per 
manufacturer’s instructions) for 5 min. 
Imaging.  Images were acquired using a Leica DM4500 microscope with a Leica DFC 340FX camera.  
Acquisition parameters were maintained identically across samples.  ERG1A (green) fluorescence in 
muscle fibers stained for either slow or fast MyHC (red) was measured. At least two fields per section, 
with three sections per muscle were photographed. 
ImageJ analysis.  Using ImageJ software, single-pixel brightness measurements were taken from the 
sarcolemma of complete fibers that also were stained for the desired type of muscle fiber (fast or slow).  
Brightness values were recorded as integers ranging from 0 (no signal) to 256 (white) and the average 
brightness value (±SEM) for each section was determined.  
Homogenization.  All the procedures were carried out on ice and all solutions contained a mixture of 
protease inhibitors (1 mM PMSF, 2 M pepstatin, 1 mM benzamidine, 8 g/ml aprotinin, 1 mM 
iodoacetamide, 1 mM 1,10-phenanthroline, 1 g/ml leupeptin).  Approximately 1 g of muscle was 
homogenized in 10 ml TE buffer (10 mM Tris, 1 mM EDTA, pH 7.5) on ice.  Nuclei and cell debris were 
removed by centrifugation (1,000 × g, 10 min).  The first supernatant was collected and the pellet was 
resuspended with 8 ml TE buffer and centrifuged (1,000 × g for 8 min).  These supernatants were pooled 
and centrifuged together at 40,000 × g for 10 min.  Supernatants were poured off and the pellets were 
resuspended in 15 ml of homogenization buffer (TE plus protease inhibitors as described above) 
containing 0.6 M potassium iodide (a chaotropic agent), and incubated on ice for 30 min. The suspension 
was then centrifuged at 40,000 × g at 4oC for 10 min.  This pellet was then resuspended by vortexing and 
recentrifuged at 40,000 × g at 4oC for 10 min three more times to remove the potassium iodide.  Finally, 
the pellet was resuspended in an appropriate amount of solubilization buffer (TE buffer as described 
above plus with 2% Triton X-100), incubated on ice for 1 hour and centrifuged at 17,400 × g at 4ºC for 30 
min to pellet insoluble materials.  Protein assays (Bio-Rad DC kit; Hercules, CA) were performed according 
to manufactures directions, and the samples were aliquoted and frozen at -70oC (Wang et al., 2006).    
Immunoblot.  Polyacrylamide SDS gels (separating gel 7.5% and stacking gel 4% acrylamide) were used 
with each electrophoresis experiment.  Aliquots of sample protein (indicated in each figure) were 
combined with sample diluting buffer (0.3M Tris, 50% glycerol, 5% SDS, 0.5M DTT, and 0.2% 
Bromophenol Blue) and boiled for five minutes.  The gel was then loaded with standard (BioRad 
Kaleidoscope Precision Plus Protein Standards; BioRad, Hercules, CA; 12l) and samples and 
electrophoresed at 200V until the dye front exited the gel. The proteins were then transferred to PVDF 
membrane (BioRad, Hercules, CA; 0.2μM pore size).  Specifically, the membrane was initially soaked in 
methanol, rinsed in deionized water, and then placed in transfer buffer (192 mM glycine, 0.1% SDS, 25 
mM Tris, pH 8.3 with 20% methanol). Once electrophoresis was complete, the gel was removed and 
transferred to PVDF membrane (Trans-Blot® Cell; BioRad). The membrane was rinsed in PBS 3 times for 
five minutes each rinse. The sample-containing membrane was then incubated in blocking buffer (0.2% 
I-Block [Applied Biosystems; Foster City, CA] and 0.1% Tween-20 in 1X PBS, pH 7.4) and rocked for one 
hour. The necessary primary antibody was diluted (per figure legends) in a second blocking buffer (5% 
NGS, 0.2% Triton X-100, 0.1% sodium azide in PBS) and the primary antibody was placed on top of the 
membrane and incubated at 4⁰C in a wet chamber overnight. The next day the membranes were 
removed from primary antibody and rocked for 10 minutes each in two changes of I-block buffer (0.2% I-
Block and 0.1% Tween-20 in 1X PBS). It was then removed from the buffer and incubated in a goat anti-
rabbit alkaline phosphatase (AP)-conjugated secondary antibody (diluted 1:1000 in I-block buffer) for 1 
hour. The secondary antibody was removed and the membranes were washed three times for 15 
minutes in I-block buffer. The membrane was then washed twice in assay buffer (0.1% Tween 20 in TBS). 
Membranes were then laid on a plastic block and Immun-Star AP substrate (BioRad, Hercules, CA) at 
37⁰C was applied to the membranes for five minutes. The substrate solution was then removed and the 
membranes were blotted and wrapped in clear plastic wrap. These were developed using a SRX-101A 
film processor (Konica Minolta, Chiyoda, Tokyo, Japan). After films were developed, they were scanned 
into a computer and ImageJ was used to measure optical densities of each band. 
Statistics.  Data from the EDL and Sol muscles were analyzed by ANOVA for a completely randomized 
design. When significant differences were found, means were separated by Fisher's Protected Least 
Significance Difference.  Data of the Gastrocnemius muscle were analyzed by a paired Students t-test. All 
data were analyzed using the General Linear Model Procedure of SAS.  
 
Results 
ERG1A Fluorescence is More Intense in Soleus than Extensor Digitorum Longus Muscles of Rats.  
Immunohistochemistry (IHC) reveals that ERG1A fluorescence intensity, as detected in the muscle fiber 
sarcolemma, is significantly greater in the Sol than in the EDL muscles of both young (39.4%) and old 
(36.5%) rats (Fig. 4 A,B).  There is no significant difference in ERG1A fluorescent intensity that can be 
attributed to age; however, there is a trend for intensity to be greater in the muscle from the older 
animals.   Immunoblots were also performed and the data show that, similar to the IHC data, ERG1A 
protein is a significant 48.3 % greater in Soleus than EDL muscles of old rats while it is 24.0% more 
abundant in Soleus than in EDL muscles of young rats (Fig. 5A-C).  Although it is not statistically 
significant, there is a another trend for ERG1A to be more abundant in old rats than in young rats. 
 
ERG1A Fluorescence is More Abundant in Slow-Twitch than Fast-Twitch Fibers of the Rat 
Gastrocnemius Muscle.  Using IHC, we determined that ERG1A is more abundant in slow-twitch fibers 
than fast-twitch fibers of rat Gastrocnemius muscle (Fig. 6 A, B), demonstrating that trends suggested by 
the results of the Sol and EDL experiments were likely caused by differences in ERG1a expression within 





 Figure 4.  ERG1A fluorescence is more 
abundant in the Soleus muscle than in 
the Extensor Digitorum Longus 
muscle of young and old rats. 
A.  Representative fluorescent images 
of Soleus (Sol) and Extensor Digitorum 
Longus (EDL) muscle sections from 
Young (3 months old) and Old (30 
months old) rats immunostained for 
ERG1A (green) and either fast or slow 
myosin heavy chain protein (red).  
Scale bars =50um 
B.  ERG1A fluorescence is significantly more abundant in the Sol than in the EDL muscles of both young 
and old rats. Each bar represents the mean fluorescent intensity ± the standard error of the mean. 
 Figure 5.  ERG1A protein is more abundant in the Soleus muscle than in the Extensor Digitorum Longus 
muscle of young and old rats. 
A.  Immunoblot of Soleus (Sol) and Extensor Digitorum Longus (EDL) muscles from 30 month old rats.  
Skeletal muscle homogenate (70 μg protein) was loaded into each lane.  Coommassie stained 
membrane below blot (in blue) indicates that equal amount of skeletal muscle homogenate were loaded 
into each lane of the gel.  
B.  Immunoblot of Sol and EDL muscles from 3 month old rats.  Skeletal muscle homogenate (70  μg 
protein) was loaded into each lane.  Coommassie stained membrane below blot (in blue) indicates that 
equal amount of skeletal muscle homogenate were loaded into each lane of the gel. 
C.  ERG1A protein is more abundant in the Sol than in the EDL muscle and this difference is statistically 
significant in the old rat skeletal muscle. Bar graph depicts mean normalized optical densities ± standard 







Figure 6.  ERG1A fluorescence is more 
abundant in slow-twitch than fast-
twitch fibers of the rat Gastrocnemius 
muscle.  
A. representative images of rat 
Gastrocnemius muscle sections. Red 
represents MyHC fluorescence used to 
determine fiber type. Green represents 
ERG1A.  Scale bars =50um. 
B. Fluorescent intensities of fast and 
slow-twitch muscle fiber sarcolemma in 




















The ERG1A channel is known to contribute to repolarization of the action potential in heart.  It was not 
detected in skeletal muscle until the Pond and Hannon labs reported finding it in atrophying skeletal 
muscle (Wang et al., 2006).  These laboratories also revealed that ectopic expression of Merg1A would 
increase UPP activity in skeletal muscle while both genetic and pharmacological block of MERG1A would 
inhibit the loss of muscle in hind limb suspended mice (Wang et al., 2006).  Further, they reported that 
ectopic expression of Merg1A would enhance the abundance of the UPP E3 ligase, MuRF1 (Hockerman 
et al., 2014), suggesting that the increase in this protein contributes to the enhanced UPP activity.  
Interestingly, the expression of Merg1a did not affect expression or abundance of the UPP E3 ligase 
atrophy marker, Mafbx/ATROGIN1 (Hockerman et al., 2014).  More work is needed to determine the 
role that the ERG1A K+ channel plays in skeletal muscle 
 In a conventional action potential, a threshold potential is reached by small depolarizing signals 
causing a committed depolarizing chain of events beginning with the opening of voltage gated sodium 
channels. These channels allow sodium to rush into the cell and greatly depolarize it. Once the cell 
depolarizes to some critical point, a second (and then perhaps even a third) set of voltage gated 
channels open and these may allow calcium to rush in to depolarize the cell further or may allow 
potassium to rush out of the cell, repolarizing it. ERG1A is a voltage gated potassium channel that aids in 
the repolarization of cells. An upregulation of ERG1a would increase the number of total potassium 
channels in the cell membrane, allowing it to repolarize faster, leading to a shorter overall action 
potential duration which may speed up the impulse generated.  
 It is known that muscle fibers can remodel themselves is response to different neural stimuli. As 
previously stated, a fast-twitch fiber receives a faster pattern of neural impulses than a slow-twitch 
fiber. If a slow-twitch fiber is reinnervated to receive the neural impulse that would normally go to a 
fast-twitch fiber, the slow-twitch fiber will remodel and become a fast twitch fiber (Schiaffino et al. 
2011). In the aforementioned cases, the neural input affects the protein expression.  It is also possible 
that in cases where the actual neural input may not be changing, that how the cell perceives and 
responds to the input may change. With an increase in the expression of Erg1a, an increase in potassium 
channels could decrease skeletal muscle action potential duration in response to neural stimulation and 
thus decrease the speed of muscle contraction.  It is well-known that skeletal muscle speed of 
contraction gets slower as animals age.  Indeed, we saw a trend for more ERG1A to be expressed in both 
old Soleus and EDL than in young Sol and EDL muscles, however these values were not significant. 
Skeletal muscle naturally atrophies with normal aging so it was expected that we would find a greater 
abundance of ERG1A within the older rats. With a larger sample size of rats, it is possible that this 
difference would become significant.  Indeed, it has been shown in humans that, even in healthy aging, 
skeletal muscle that is retained by exercise becomes slower with an increase in slow-type fibers which 
appear in clusters within skeletal muscle sections (Mosole et al., 2014 ).  We see a trend here for there 
to be a greater abundance of ERG1A in the skeletal muscle of the older rats.  Indeed, the ERG1A channel 
could be contributing to this remodeling.  It is also possible that ERG1 could be contributing to the 
changes in metabolism that occur with the fiber-type switching.  Indeed, slow-twitch fibers prioritize the 
use of aerobic respiration while fast-twitch fiber variants 2X and 2B prioritize anaerobic metabolism. 
This switch to more anaerobic metabolism may be beneficial in an atrophying muscle as it may promote 
the breakdown of internal energy storages. Further research is needed to determine the reason for this 




Using IHC, we determined that in the young rats (3 months) there was a 39.4% difference in ERG1A 
expression with more in the Soleus than in the EDL. In the old rats (30 months) there was 36.5% more 
ERG1a protein in the Soleus than in the EDL muscle. Both differences were significant (p<0.001).  We 
confirmed these finding in immunoblot showing a 48.3% difference in ERG expression in old rats and a 
24% difference in expression in the young rats. Only the difference observed in old rats was significant 
(p< 0.05).  Because Soleus is very homogeneous for slow-type fibers, we hypothesized that this fiber 
type would contain more ERG1A protein.  Indeed, using IHC we revealed that there is more ERG1A 
protein in slow-type than in fast-type fibers.  It is possible that this membrane bound voltage-gated 
channel is affecting the duration of the action potential generated and, thus, slowing the speed of 
contraction.   Indeed, both aged and atrophic skeletal muscle exhibit slower rates of contraction (Lecker 
et al. 1999).  We know that ERG1a also affects UPP activity in response to atrophic stimuli, however, 
little is known about the mechanism(s) by which it has its effect. Future studies would explore these 
facets of the ERG1a channel detected I skeletal muscle membrane.  Indeed, there is a need for improved 
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